Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Cimigenol 3-o-alpha-l-arabinopyranoside
2. Cimigenol 3aap
1. Cimicifugoside M
2. 256925-92-5
3. Cimigenol-3-o-alpha-l-arabinoside
4. 4dc28j6r1k
5. (2s,3r,4s,5s)-2-[[(1s,2r,3s,4r,7r,9s,12r,14s,17r,18r,19r,21r,22s)-2-hydroxy-22-(2-hydroxypropan-2-yl)-3,8,8,17,19-pentamethyl-23,24-dioxaheptacyclo[19.2.1.01,18.03,17.04,14.07,12.012,14]tetracosan-9-yl]oxy]oxane-3,4,5-triol
6. Unii-4dc28j6r1k
7. Cimigenol 3-o-alpha-l-arabinoside
8. Cimigenol 3-o-alpha-l-arabinopyranoside
9. Schembl4921749
10. Zinc96023692
11. Akos032948479
12. Akos037514588
13. Alpha-l-arabinopyranoside, (3beta,15alpha,16alpha,23r,24s)-16,23:16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl
14. Cimigenol 3-o-.alpha.-l-arabinoside
15. Cimigenol-3-o-.alpha.-l-arabinoside
16. Cimigenol 3-o-.alpha.-l-arabinopyranoside
17. Q27259441
18. Cimigenol 3-o-.alpha.-l-arabinopyranoside (constituent Of Black Cohosh) [dsc]
19. .alpha.-l-arabinopyranoside, (3.beta.,15.alpha.,16.alpha.,23r,24s)-16,23:16,24-diepoxy-15,25-dihydroxy-9,19-cyclolanostan-3-yl
| Molecular Weight | 620.8 g/mol |
|---|---|
| Molecular Formula | C35H56O9 |
| XLogP3 | 3.7 |
| Hydrogen Bond Donor Count | 5 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 3 |
| Exact Mass | 620.39243336 g/mol |
| Monoisotopic Mass | 620.39243336 g/mol |
| Topological Polar Surface Area | 138 Ų |
| Heavy Atom Count | 44 |
| Formal Charge | 0 |
| Complexity | 1210 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 17 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Cimicifugoside M manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cimicifugoside M, including repackagers and relabelers. The FDA regulates Cimicifugoside M manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cimicifugoside M API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cimicifugoside M supplier is an individual or a company that provides Cimicifugoside M active pharmaceutical ingredient (API) or Cimicifugoside M finished formulations upon request. The Cimicifugoside M suppliers may include Cimicifugoside M API manufacturers, exporters, distributors and traders.
Cimicifugoside M Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cimicifugoside M GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cimicifugoside M GMP manufacturer or Cimicifugoside M GMP API supplier for your needs.
A Cimicifugoside M CoA (Certificate of Analysis) is a formal document that attests to Cimicifugoside M's compliance with Cimicifugoside M specifications and serves as a tool for batch-level quality control.
Cimicifugoside M CoA mostly includes findings from lab analyses of a specific batch. For each Cimicifugoside M CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cimicifugoside M may be tested according to a variety of international standards, such as European Pharmacopoeia (Cimicifugoside M EP), Cimicifugoside M JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cimicifugoside M USP).
LOOKING FOR A SUPPLIER?
